A number of firms have modified their ratings and price targets on shares of Zai Lab (NASDAQ: ZLAB) recently:

  • 9/12/2018 – Zai Lab was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company’s product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China. “
  • 9/7/2018 – Zai Lab was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 9/6/2018 – Zai Lab was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company’s product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China. “
  • 8/30/2018 – Zai Lab was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 8/29/2018 – Zai Lab was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $27.00 price target on the stock. According to Zacks, “Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company’s product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China. “
  • 8/21/2018 – Zai Lab was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company’s product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China. “
  • 8/15/2018 – Zai Lab was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company’s product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China. “
  • 8/2/2018 – Zai Lab was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/27/2018 – Zai Lab was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.

ZLAB traded down $0.28 on Tuesday, hitting $18.31. The company had a trading volume of 3,344 shares, compared to its average volume of 407,770. The firm has a market cap of $1.07 billion and a P/E ratio of -7.89. Zai Lab Ltd has a 12-month low of $17.17 and a 12-month high of $35.74.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC grew its position in Zai Lab by 3.9% in the second quarter. FMR LLC now owns 5,055,427 shares of the company’s stock worth $117,539,000 after acquiring an additional 188,745 shares in the last quarter. Millennium Management LLC boosted its position in shares of Zai Lab by 255.1% during the second quarter. Millennium Management LLC now owns 383,885 shares of the company’s stock valued at $8,925,000 after buying an additional 275,794 shares during the period. Orbimed Advisors LLC boosted its position in shares of Zai Lab by 144.8% during the second quarter. Orbimed Advisors LLC now owns 1,611,000 shares of the company’s stock valued at $37,456,000 after buying an additional 952,840 shares during the period. BlackRock Inc. boosted its position in shares of Zai Lab by 205.2% during the second quarter. BlackRock Inc. now owns 63,368 shares of the company’s stock valued at $1,473,000 after buying an additional 42,608 shares during the period. Finally, Segantii Capital Management Ltd boosted its position in shares of Zai Lab by 38.8% during the second quarter. Segantii Capital Management Ltd now owns 534,445 shares of the company’s stock valued at $12,426,000 after buying an additional 149,445 shares during the period. Institutional investors own 24.38% of the company’s stock.

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.

Further Reading: Earnings Per Share (EPS)

Receive News & Ratings for Zai Lab Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab Ltd and related companies with MarketBeat.com's FREE daily email newsletter.